Bli medlem
Bli medlem

Du är här


Elekta: NHS Supply Chain chooses Elekta to upgrade UK's radiotherapy resources

CRAWLEY, UK, May 12, 2016 - The UK's NHS Supply Chain (NHSSC) has
signed an order to acquire linear accelerators (linacs) and software
from Elekta (EKTA-B.ST) for a total value of GBP 21.5 million. The
order was booked in the fourth quarter of Elekta's fiscal year

The order includes Elekta Synergy® (
linacs with Agility™ ( multileaf
collimators for high speed beam shaping. The Synergy linacs also
include VMAT, which improves radiation therapy treatment speed and
dose reduction to the patient.

Andy Brown, Managing Director of NHS Supply Chain Capital Solutions,
says: "The Capital Team supports patient care by delivering the
latest equipment at the best value. These systems are a key part of
delivering world class cancer care and by using the Department of
Health's Capital Equipment fund to support the bulk procurement with
Elekta Ltd, we have released greater value for trusts and savings
back to the NHS."

François Pointurier, Senior Vice President, Region Europe and AFLAME
at Elekta says: "This order comes on the tail of a recent study in
the Green Journal (Radiotherapy & Oncology) titled `Radiotherapy in
Europe: An unmet need?' Elekta is delighted to be part of the
solution by supporting the NHS in their investment to address this
situation and help improve the lives of patients with cancer in the

Paddy Greally, Elekta's Managing Director for the UK and Ireland,
says: "Elekta is delighted to continue our relationship with NHSSC
and our long-term commitment to radiotherapy in the UK. We are
especially proud to deliver this equipment to treat cancer from our
international linac manufacturing site in Crawley."

All equipment and software will be delivered over the next 24 months.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta

Tel: +31 653 561 242, e-mail:
Time zone: CET: Central European Time
Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail:
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public
in accordance with the Securities Market Act and/or the Financial
Instruments Trading Act. The information was published at 07:30 CET
on May 12, 2016.

About Elekta
Elekta is a human care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The
company develops sophisticated, state-of-the-art tools and treatment
planning systems for radiation therapy, radiosurgery and
brachytherapy, as well as workflow enhancing software systems across
the spectrum of cancer care. Stretching the boundaries of science and
technology, providing intelligent and resource-efficient solutions
that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over
6,000 hospitals worldwide. Elekta employs around 3,800 employees
globally. The corporate headquarters is located in Stockholm, Sweden,
and the company is listed on NASDAQ Stockholm. Website:


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.